1. Volume 13, Issue 1, Pages 221-228 (January 2006)
Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme 
Arnold I. Freeman, Zichria Zakay-Rones, John M. Gomori, Eduard Linetsky, Linda Rasooly, Evgeniya Greenbaum, Shira Rozenman- Yair, Amos Panet, Eugene Libson, Charles S. Irving, Eithan Galun, Tali Siegal 
Molecular Therapy 
Volume 13, Issue 1, Pages (January 2006)
DOI: /j.ymthe
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

2. FIG. 1 Patient enrollment.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

3. FIG. 2
Complete tumor response. (A) Patient 09 at baseline, (B) stable disease at first follow-up, (C) partial response (PR) at second follow-up, (D) PR at 20 weeks from start of virotherapy, and (E and F) complete response at 25 and 30 weeks from start of virotherapy.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

4. Supplementary Fig. 1
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2005 The American Society of Gene Therapy Terms and Conditions